Mayne Pharma Group Aktie
| 2,90EUR | -0,20EUR | -6,45% |
WKN DE: A1C821 / ISIN: AU000000MYX0
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 900 | 0 | 450 | 450 | 0 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,45 | 0,00 | 0,41 | 0,86 | 0,00 |
Bilanz (in Mio. AUD) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 417 | 512 | 554 | 461 | 353 |
| Summe Anlagevermögen | 1 062 | 791 | 695 | 683 | 662 |
| Summe Aktiva | 1 478 | 1 303 | 1 248 | 1 143 | 1 015 |
Bilanz (in Mio. AUD) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 707 | 746 | 614 | 689 | 644 |
| Summe Eigenkapital | 772 | 557 | 634 | 454 | 370 |
| Summe Passiva | 1 478 | 1 303 | 1 248 | 1 143 | 1 015 |
Adresse
| 1538 Main North Road, 5106 Salisbury | |
| Telefon | +61 (8) 8209-2666 |
| Fax | +61 (8) 8281-0284 |
| Internet | http://www.maynepharma.com |
Management
|
Aaron Gray
Chief Financial Officer |
|
Ann Custin
Non-Executive Director |
|
Anne Lockwood
Non-Executive Director |
|
Brant Schofield
Executive Vice President-Corporate Development |
|
Bruce G. Robinson
Independent Non-Executive Director |
|
David Petrie
Non-Executive Director |
|
Erinn Nathaniel
Director-Human Resources |
|
Frank C. Condella
Chairman |
|
Frank Casty
Chief Medical Officer & EVP |
|
Kathryn MacFarlane
Non-Executive Director |
|
Keith Moore
Vice President-Research & Development |
|
Kimberly Parker
Executive Vice President & General Counsel |
|
Laura Loftus
Secretary & Associate General Counsel |
|
Patrick J. Blake
Independent Non-Executive Director |
|
Richard Moldin
President-Generics Products Division |
|
Shawn Patrick O'Brien
Chief Executive Officer, Director & MD |
|
Thomas Duthy
Investor Relation Contact |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.